New cheaper eye drug shows promise against leading cause of blindness
Disease control
Completed
This completed Phase 3 study tested whether a new, potentially more affordable biosimilar version of the drug aflibercept (FYB203) works as well and is as safe as the established drug Eylea for treating wet age-related macular degeneration (AMD). The study involved 434 patients w…
Phase: PHASE3 • Sponsor: Bioeq GmbH • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC